Massimo Spada

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7540386/publications.pdf

Version: 2024-02-01

52	4,444	147801	182427
papers	citations	31 h-index	51 g-index

53	53	53	6577
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	In vivo antiaging effects of alkaline water supplementation. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 657-664.	5.2	10
2	Beneficial Effects of Fermented Papaya Preparation (FPPÂ®) Supplementation on Redox Balance and Aging in a Mouse Model. Antioxidants, 2020, 9, 144.	5.1	12
3	A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors. Cell Death and Disease, 2019, 10, 529.	6.3	37
4	Autoantibodies Specific to ERÎ± are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer. Cells, 2019, 8, 750.	4.1	8
5	Lenalidomide improves the therapeutic effect of an interferon-Î±-dendritic cell-based lymphoma vaccine. Cancer Immunology, Immunotherapy, 2019, 68, 1791-1804.	4.2	18
6	Oral Administration of Fermented Papaya (FPPÂ®) Controls the Growth of a Murine Melanoma through the In Vivo Induction of a Natural Antioxidant Response. Cancers, 2019, 11, 118.	3.7	9
7	Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNÎ±-Dendritic Cells and Rituximab: a Phase I Clinical Trial. Clinical Cancer Research, 2019, 25, 5231-5241.	7.0	34
8	Joint action of miRâ€126 and MAPK/PI3K inhibitors against metastatic melanoma. Molecular Oncology, 2019, 13, 1836-1854.	4.6	15
9	Inflammatory cytokines associated with cancer growth induce mitochondria and cytoskeleton alterations in cardiomyocytes. Journal of Cellular Physiology, 2019, 234, 20453-20468.	4.1	29
10	IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. OncoImmunology, 2017, 6, e1317420.	4.6	137
11	Biphasic effects of propranolol on tumour growth in B16F10 melanomaâ€bearing mice. British Journal of Pharmacology, 2017, 174, 139-149.	5.4	34
12	Combining Type I Interferons and 5-Aza-2â€²-Deoxycitidine to Improve Anti-Tumor Response against Melanoma. Journal of Investigative Dermatology, 2017, 137, 159-169.	0.7	60
13	New derivatives of the antimalarial drug Pyrimethamine in the control of melanoma tumor growth: an in vitro and in vivo study. Journal of Experimental and Clinical Cancer Research, 2016, 35, 137.	8.6	21
14	CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis. Nanoscale, 2016, 8, 7562-7571.	5.6	15
15	IFN-Î± potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer. Oncotarget, 2016, 7, 26361-26373.	1.8	25
16	Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells. International Journal of Cancer, 2015, 137, 1491-1497.	5.1	34
17	Optimization of Mucosal Responses after Intramuscular Immunization with Integrase Defective Lentiviral Vector. PLoS ONE, 2014, 9, e107377.	2.5	12
18	A multidisciplinary study usingin vivotumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells. Journal of Immunotoxicology, 2014, 11, 337-346.	1.7	48

#	Article	IF	Citations
19	Murine Granulocyteâ€“Macrophage Colony-Stimulating Factor Expressed from a Bicistronic Simian Immunodeficiency Virus-Based Integrase-Defective Lentiviral Vector Does Not Enhance T-Cell Responses in Mice. Viral Immunology, 2014, 27, 512-520.	1.3	1
20	Abstract 1656: CXCR4 antagonist-expressing liposomes reduce lung metastases and deliver drugs to CXCR4 expressing cells: a new drug-targeting device. , 2014, , .		0
21	IRF-8 Controls Melanoma Progression by Regulating the Cross Talk between Cancer and Immune Cells within the Tumor Microenvironment. Neoplasia, 2012, 14, 1223-IN43.	5.3	48
22	Characterisation of in vivo ovarian cancer models by quantitative ¹H magnetic resonance spectroscopy and diffusionâ€weighted imaging. NMR in Biomedicine, 2012, 25, 632-642.	2.8	30
23	Type I IFNs Control Antigen Retention and Survival of CD8Î±+ Dendritic Cells after Uptake of Tumor Apoptotic Cells Leading to Cross-Priming. Journal of Immunology, 2011, 186, 5142-5150.	0.8	110
24	Nonintegrating Lentiviral Vector-Based Vaccine Efficiently Induces Functional and Persistent CD8+ T Cell Responses in Mice. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-7.	3.0	20
25	High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients. PLoS ONE, 2009, 4, e5219.	2.5	806
26	Pleiotropic function of ezrin in human metastatic melanomas. International Journal of Cancer, 2009, 124, 2804-2812.	5.1	41
27	In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma. European Journal of Cancer, 2009, 45, 2606-2617.	2.8	30
28	Development and use of SIV-based Integrase defective lentiviral vector for immunization. Vaccine, 2009, 27, 4622-4629.	3.8	41
29	Pyrimethamine Induces Apoptosis of Melanoma Cells via a Caspase and Cathepsin Double-Edged Mechanism. Cancer Research, 2008, 68, 5291-5300.	0.9	37
30	Proton Pump Inhibitors Induce Apoptosis of Human B-Cell Tumors through a Caspase-Independent Mechanism Involving Reactive Oxygen Species. Cancer Research, 2007, 67, 5408-5417.	0.9	280
31	Successful Immunization with a Single Injection of Non-integrating Lentiviral Vector. Molecular Therapy, 2007, 15, 1716-1723.	8.2	79
32	Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus. Vaccine, 2006, 24, S56-S57.	3.8	33
33	IFN-Î±-conditioned dendritic cells are highly efficient in inducing cross-priming CD8+ T cells against exogenous viral antigens. European Journal of Immunology, 2006, 36, 2046-2060.	2.9	132
34	Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID mice. International Immunology, 2005, 17, 469-475.	4.0	22
35	Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine, 2005, 23, 2994-3004.	3.8	88
36	Effect of Proton Pump Inhibitor Pretreatment on Resistance of Solid Tumors to Cytotoxic Drugs. Journal of the National Cancer Institute, 2004, 96, 1702-1713.	6.3	395

#	Article	IF	Citations
37	Effect Of Human Natural Killer and Î³Î´ T Cells on the Growth of Human Autologous Melanoma Xenografts in SCID Mice. Cancer Research, 2004, 64, 378-385.	0.9	90
38	Potent Immune Response against HIV-1 and Protection from Virus Challenge in hu-PBL-SCID Mice Immunized with Inactivated Virus-pulsed Dendritic Cells Generated in the Presence of IFN-Î±. Journal of Experimental Medicine, 2003, 198, 361-367.	8.5	130
39	Monocyte-Derived Dendritic Cells Generated After a Short-Term Culture with IFN-Î± and Granulocyte-Macrophage Colony-Stimulating Factor Stimulate a Potent Epstein-Barr Virus-Specific CD8+ T Cell Response. Journal of Immunology, 2003, 170, 5195-5202.	0.8	79
40	Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD4+ T lymphocytes in hu-SCID mice. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8927-8932.	7.1	40
41	Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. Aids, 2003, 17, 1597-1604.	2.2	110
42	Chimeric Plant Virus Particles as Immunogens for Inducing Murine and Human Immune Responses against Human Immunodeficiency Virus Type 1. Journal of Virology, 2001, 75, 8434-8439.	3.4	173
43	Expression of CCR-7, MIP-3Î², and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood, 2001, 98, 3022-3029.	1.4	231
44	Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides. Aids, 2001, 15, 2231-2238.	2.2	41
45	Primary HIV-1 infection of human CD4+ T cells passaged into SCID mice leads to selection of chronically infected cells through a massive Fas-mediated autocrine suicide of uninfected cells. Cell Death and Differentiation, 2000, 7, 37-47.	11.2	12
46	Type I Interferon as a Powerful Adjuvant for Monocyte-Derived Dendritic Cell Development and Activity in Vitro and in Hu-Pbl-Scid Mice. Journal of Experimental Medicine, 2000, 191, 1777-1788.	8.5	590
47	Type I Interferon Is a Powerful Inhibitor of in Vivo HIV-1 Infection and Preserves Human CD4+ T Cells from Virus-Induced Depletion in SCID Mice Transplanted with Human Cells. Virology, 1999, 263, 78-88.	2.4	57
48	Human Immunodeficiency Virus Type 1 Strains R5 and X4 Induce Different Pathogenic Effects in hu-PBL-SCID Mice, Depending on the State of Activation/Differentiation of Human Target Cells at the Time of Primary Infection. Journal of Virology, 1999, 73, 6453-6459.	3.4	43
49	TREATMENT OF SEVERE COMBINED IMMUNODEFICIENCY MICE WITH ANTI-MURINE GRANULOCYTE MONOCLONAL ANTIBODY IMPROVES HUMAN LEUKOCYTE XENOTRANSPLANTATION1. Transplantation, 1998, 65, 416-420.	1.0	17
50	Human Lymphoblastoid CD4 ⁺ T Cells Become Permissive to Macrophage-Tropic Strains of Human Immunodeficiency Virus Type 1 after Passage into Severe Combined Immunodeficient Mice through In Vivo Upregulation of CCR5: In Vivo Dynamics of CD4 ⁺ T-Cell Differentiation in Pathogenesis of AIDS. Journal of Virology, 1998, 72, 10323-10327.	3.4	12
51	U937-SCID mouse xenografts: a new model for acute in vivo HIV-1 infection suitable to test antiviral strategies. Antiviral Research, 1997, 36, 81-90.	4.1	19
52	T-cell dysfunctions in hu-PBL-SCID mice infected with human immunodeficiency virus (HIV) shortly after reconstitution: in vivo effects of HIV on highly activated human immune cells. Journal of Virology, 1996, 70, 7958-7964.	3.4	49